private:kinodyn
|
5040591
|
May 29th, 2019 12:00AM
|
KinoDyn, Inc.
|
25
|
0.00
|
Open
|
Biotechnology
|
May 29th, 2019 08:59AM
|
May 29th, 2019 08:59AM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
Open
|
|
Open
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Mar 19th, 2018 12:00AM
|
KinoDyn, Inc.
|
22
|
0.00
|
Open
|
Biotechnology
|
Mar 18th, 2018 11:01PM
|
Mar 18th, 2018 11:01PM
|
|
Open
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Feb 17th, 2018 12:00AM
|
KinoDyn, Inc.
|
21
|
0.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Feb 16th, 2018 12:00AM
|
KinoDyn, Inc.
|
21
|
0.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Feb 15th, 2018 12:00AM
|
KinoDyn, Inc.
|
21
|
0.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Feb 14th, 2018 12:00AM
|
KinoDyn, Inc.
|
21
|
0.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Feb 13th, 2018 12:00AM
|
KinoDyn, Inc.
|
21
|
0.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Feb 12th, 2018 12:00AM
|
KinoDyn, Inc.
|
21
|
0.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Feb 11th, 2018 12:00AM
|
KinoDyn, Inc.
|
21
|
0.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|
private:kinodyn
|
5040591
|
Feb 10th, 2018 12:00AM
|
KinoDyn, Inc.
|
21
|
0.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
KinoDyn, Inc. is a Chapel Hill-based cancer drug discovery company built around a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.
|
|
|
|
|
|
|
|
|
|
KinoDyn
|
|
|